OmniAb Results Presentation Deck

Approved and Clinical-Stage Partner Pipeline as of 12/31/2022 THREE APPROVED PRODUCTS AND 23 ACTIVE CLINICAL-STAGE ANTIBODIES Phase 3 Target Therapy Area Oncology Oncology Oncology Immunology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Metabolic Partner Program gloria ARCUS GILEAD Zimberelimab G 基石药业 CSTONE Pfizer EQRX PAMACEUTICALS HANALL Janssen Jehon HARBOUR IMMUNOVANT BIONED Genentech A Member of the Rache Group Genmab BIONTECH MERCK Aptevo Janssen Janssen HẬU CÁC TH Genmab OCTTQ Ch symphogen a Servier Company symphogen a Servier Company symphogen a Servier Company abbvie AstraZeneca AMGEN SalubrisBio CURON Zhilkang Hongyi Boehringer Undisclosed Merck Genmab BIONTECH Janssen Sugemalimab Teclistamab Batoclimab Tiragolumab GEN1046 M6223 APVO436 JNJ-70218902 JNJ-78306358 GEN1047 S095017 S095018 S095024 S095029 ABBV-383 TNB-486 AMG 340 SAL003 CN1 Undisclosed Undisclosed Undisclosed M9140 GEN1053 JNJ-79635322 Source Animal OmniRat OmniRat OmniRat OmniRat OmniRat OmniRat OmniRat OmniMouse OmniRat OmniRat OmniRat OmniRat OmniRat OmniRat OmniRat OmniFlic OmniFlic OmniFlic OmniRat OmniRat OmniRat OmniChicken OmniRat OmniRat OmniRat OmniRat Oncology Oncology Undisclosed PD-1 PD-L1 BCMA x CD3 FcRn TIGIT PD-L1 x 4-1BB TIGIT CD123 x CD3 Undisclosed HLA-G x CD3 B7H4 x CD3 LAG-3 TIM-3 CD73 NKG2A BCMA x CD3 CD19 x CD3 PSMA x CD3 PCSK9 Undisclosed Undisclosed Undisclosed Gastrointestinal Undisclosed CEACAM-5 CD27 Undisclosed Oncology Oncology Oncology Phase 1 Phase 2 Registration Approved Animal launch year: OmniRat 2012; OmniMouse 2014; OmniFlic 2014; OmniChicken 2016; OmniClic 2019; OmniTaur 2020 Notes: Most advanced status for each program shown. Zimberelimab and Sugemalimab are approved and marketed in China. Teclistamab is approved and marketed in the US and EU with $35M launch milestones paid. Indicates program with fully paid license from OMT, Inc. prior to acquisition. Programs discovered by Teneobio under a fully paid license. Future programs discovered under license agreement are subject to downstream economics. 22 OmniAb

View entire presentation